Ardelyx (ARDX) Resubmits New Drug Application to FDA.
WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize...
And we Have Another Triple! Ardelyx (ARDX) Touches $5.00, up 333%.
LIVE QUOTE
Ardelyx Enters the Danger Zone* With Tenapanor.
The company produced favorable (albeit very technical) information (data) at the National Kidney Foundation 2023 Spring Clinical...
Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment...
Topline Results anticipated by the end of Q2 2023
CRANFORD, N.J. , April 3, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced...
And We Have a $26.4 Billion Winning Trifecta!
THREE PREVIOUS WINNERS*
Immunomedics (IMMU) $3 to $87 up 2,800%, a gain of $20.7 billion. Acquired by Gilead Sciences (GILD)
Dicerna (DRNA) $3.30 to $38.25 up...
Sanofi (SNY) to Acquire Provention Bio (PRVB) for $25 a Share. Gains 243%.
Up 416%, from Adding it to 2022 Watch List!
Great way to wake up after a night of hard partying at the C-3.
How pray tell,...
We’re Bearish, but we’re up 243% in Provention Bio (PRVB) Today.
And up 416%, from Adding it to 2022 Watch List!
Great way to wake up after a night of hard partying at the C-3.
How pray...
Unicycive Therapeutics (UNCY) $2.73 Tacks on Another 30%. We’re now up 249%.
Stormin..Live Quote
We're still not sure how to pronounce it...but Wall Street likes it.
News Archive
Unicycive Therapeutics (UNCY) $2.73. We're now up 249%.
Unicycive (UNCY) Shoots and...
New Player in the Electric Vehicle (EV) Market?
Principal Solar (PSWW) Highlights one of it's Portfolio Holdings, eTruck Transportation.
Alternative Energy Stock Review
The exciting thing about Principal Solar (PSWW), a tiny energy and...
Unicycive (UNCY) Shoots and Scores, up 40% Today!
We're up 126% Since December, and That Ain't Bad.
Note: This isn't the end, it's just the beginning.
LIVE QUOTE
Adding Unicycive (UNCY) $0.75 to...
The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers. Unicyive...
Los Altos, CA --News Direct-- Unicycive Therapeutics, Inc.
By Julian Richard, Benzinga
Unicycive Therapeutics Inc (NASDAQ: UNCY) is a biopharmaceutical company committed to developing effective and safe...
Latest article
Jeffrey Gundlach: Reckoning is Coming.
Jeffrey Edward Gundlach is a businessman, fund manager, and philanthropist. He is the founder of DoubleLine Capital, an investment firm.
On 11 November 2020, Gundlach remarked in an interview with...
Who’s the Next Eric Sprott?
To say Eric Sprott has left a legendary mark on the world of mining investment would be an understatement. With a career spanning five...
Perpetua (PPTA) Raises $300 Million.
Not a bad day in Idaho. $300 million banked! We look at the dip as a buying opportunity, as does John Paulson & Co.,...
